Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Sage Therapeutics participates in a conference call hosted by Wolfe Research » 10:25
07/09/20
07/09
10:25
07/09/20
10:25
SAGE

Sage Therapeutics

$44.53 /

+0.235 (+0.53%)

Wolfe Research Biotech…

Wolfe Research Biotech Analyst Tewari holds a conference call with Chief Scientific Officer Robichaud and VP of Pharmacology Quirk on July 9 at 11 am.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$44.53 /

+0.235 (+0.53%)

SAGE Sage Therapeutics
$44.53 /

+0.235 (+0.53%)

05/26/20 RBC Capital
Sage Therapeutics price target raised to $75 from $72 at RBC Capital
05/08/20 Wedbush
Sage Therapeutics downgraded at Wedbush on lack of catalysts
05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
SAGE Sage Therapeutics
$44.53 /

+0.235 (+0.53%)

Tuesday
Conference/Events
Sage Therapeutics participates in a conference call hosted by Wolfe Research » 09:34
07/07/20
07/07
09:34
07/07/20
09:34
SAGE

Sage Therapeutics

$41.90 /

-1.12 (-2.60%)

Wolfe Research Biotech…

Wolfe Research Biotech Analyst Tewari holds a conference call with Chief Scientific Officer Robichaud and VP of Pharmacology Quirk on July 9 at 11 am.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$41.90 /

-1.12 (-2.60%)

SAGE Sage Therapeutics
$41.90 /

-1.12 (-2.60%)

05/26/20 RBC Capital
Sage Therapeutics price target raised to $75 from $72 at RBC Capital
05/08/20 Wedbush
Sage Therapeutics downgraded at Wedbush on lack of catalysts
05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
SAGE Sage Therapeutics
$41.90 /

-1.12 (-2.60%)

Over a month ago
Recommendations
Sage Therapeutics price target raised to $75 from $72 at RBC Capital » 09:14
05/26/20
05/26
09:14
05/26/20
09:14
SAGE

Sage Therapeutics

$38.99 /

+0.99 (+2.61%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Sage Therapeutics to $75 from $72 and keeps an Outperform rating on the shares. A deep dive analysis into the company's NMDA portfolio suggests that its is underappreciated with long-term upside potential, the analyst tells investors in a research note. Abrahams sees Sage's lead pipeline asset '718 as "interesting" as it has produced "intriguing" data based on the mechanism that could provide benefits across a number of different neuropsych indication. The analyst adds that the company's oral antidepressant drug '217 has a lower-risk path than previously anticipated.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$38.99 /

+0.99 (+2.61%)

SAGE Sage Therapeutics
$38.99 /

+0.99 (+2.61%)

05/08/20 Wedbush
Sage Therapeutics downgraded at Wedbush on lack of catalysts
05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
04/09/20 BMO Capital
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital
SAGE Sage Therapeutics
$38.99 /

+0.99 (+2.61%)

SAGE Sage Therapeutics
$38.99 /

+0.99 (+2.61%)

Downgrade
Sage Therapeutics downgraded at Wedbush on lack of catalysts » 07:18
05/08/20
05/08
07:18
05/08/20
07:18
SAGE

Sage Therapeutics

$40.65 /

-0.06 (-0.15%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico downgraded Sage Therapeutics to Neutral from Outperform with a price target of $37, up from $36. Chico says that while shares have rallied 44% from the lows seen in early April, it is difficult to find near-term catalysts that can help shares continue working higher. Chico continues to see zuranolone as an active agent and thinks higher dosing at the 50mg level is likely to improve any potential exposure limitations, but with key studies initiating and disruptions across the sector impacting clinical trial enrollment, Chico sees risk to rapid advancement of the development program and awaita better visibility into the pace of clinical trial enrollment and/or how the 50mg zuranolone dose performs.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$40.65 /

-0.06 (-0.15%)

05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
04/09/20 BMO Capital
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital
04/08/20 Wedbush
Sage Therapeutics price target lowered to $36 from $56 at Wedbush
Downgrade
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush » 06:45
05/08/20
05/08
06:45
05/08/20
06:45
SAGE

Sage Therapeutics

$40.65 /

-0.06 (-0.15%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico downgraded Sage Therapeutics to Neutral from Outperform.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$40.65 /

-0.06 (-0.15%)

05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
04/09/20 BMO Capital
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital
04/08/20 Wedbush
Sage Therapeutics price target lowered to $36 from $56 at Wedbush
04/08/20 Oppenheimer
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer
Recommendations
Sage Therapeutics price target raised to $44 from $36 at Mizuho » 06:39
05/08/20
05/08
06:39
05/08/20
06:39
SAGE

Sage Therapeutics

$40.65 /

-0.06 (-0.15%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan raised the firm's price target on Sage Therapeutics to $44 from $36 and keeps a Neutral rating on the shares following the company's Q1 results. Lower expenses helped Sage deliver a smaller than expected Q1 loss per share, but the focus remains on the company's ability to salvage the zuranolone clinical program, Divan tells investors in a research note.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$40.65 /

-0.06 (-0.15%)

04/09/20 BMO Capital
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital
04/08/20 Wedbush
Sage Therapeutics price target lowered to $36 from $56 at Wedbush
04/08/20 Oppenheimer
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer
04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
Earnings
Sage Therapeutics reports Q1 EPS ($2.44), consensus ($3.14) » 16:30
05/07/20
05/07
16:30
05/07/20
16:30
SAGE

Sage Therapeutics

$40.65 /

-0.06 (-0.15%)

Cash, cash equivalents,…

Cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2020 were approximately $0.9 billion compared to $1.0 billion at December 31, 2019.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$40.65 /

-0.06 (-0.15%)

04/09/20 BMO Capital
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital
04/08/20 Wedbush
Sage Therapeutics price target lowered to $36 from $56 at Wedbush
04/08/20 Oppenheimer
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer
04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
Over a quarter ago
Recommendations
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital » 09:27
04/09/20
04/09
09:27
04/09/20
09:27
SAGE

Sage Therapeutics

$30.00 /

+1.16 (+4.02%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman lowered the firm's price target on Sage Therapeutics to $65 from $86 but keeps an Outperform rating on the shares. The analyst says the company's corporate restructuring announcement to free up $170M in cost savings is not surprising given the uncertain COVID-19 environment, adding that he agrees with the decision to prioritize resources to higher-value opportunities in the pipeline. Nachman also cuts his FY20 and FY21 EPS views on Sage to ($8.25) from ($9.39) and to ($5.67) from ($7.25).

ShowHide Related Items >><<
SAGE Sage Therapeutics
$30.00 /

+1.16 (+4.02%)

04/08/20 Wedbush
Sage Therapeutics price target lowered to $36 from $56 at Wedbush
04/08/20 Oppenheimer
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer
04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
04/08/20 Mizuho
Sage Therapeutics price target lowered to $36 from $58 at Mizuho
Recommendations
Sage Therapeutics price target lowered to $36 from $56 at Wedbush » 09:09
04/08/20
04/08
09:09
04/08/20
09:09
SAGE

Sage Therapeutics

$28.84 /

+0.5 (+1.76%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico lowered the firm's price target on Sage Therapeutics to $36 from $56 and keeps an Outperform rating on the shares. The analyst notes that with SAGE-217 efforts requiring more time and capital, and Zulresso facing commercial headwinds, the company's announced restructuring is unsurprising and represents a necessary cost-savings move to advance development campaigns.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$28.84 /

+0.5 (+1.76%)

04/08/20 Oppenheimer
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer
04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
04/08/20 Mizuho
Sage Therapeutics price target lowered to $36 from $58 at Mizuho
04/08/20 Citi
Sage Therapeutics price target raised to $54 from $48 at Citi
Recommendations
Sage Therapeutics price target lowered to $50 from $60 at Oppenheimer » 07:55
04/08/20
04/08
07:55
04/08/20
07:55
SAGE

Sage Therapeutics

$28.84 /

+0.5 (+1.76%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson lowered the firm's price target on Sage Therapeutics to $50 from $60 and keeps an Outperform rating on the shares. The analyst notes that the company announced a massive restructuring that appears to abandon the launch of Zulresso. Olson suspects that primary focus will indefinitely remain on zuranolone and pipeline assets, and dramatically lowers his Zulresso sales forecast.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$28.84 /

+0.5 (+1.76%)

04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
04/08/20 Mizuho
Sage Therapeutics price target lowered to $36 from $58 at Mizuho
04/08/20 Citi
Sage Therapeutics price target raised to $54 from $48 at Citi
04/08/20 Guggenheim
Sage Therapeutics downgraded to Neutral from Buy at Guggenheim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.